Published in Lancet Oncol on September 01, 2011
Global surveillance of cancer survival 1995-2009: analysis of individual data for 25,676,887 patients from 279 population-based registries in 67 countries (CONCORD-2). Lancet (2014) 8.59
Applying what we know to accelerate cancer prevention. Sci Transl Med (2012) 2.43
Delivering high-quality and affordable care throughout the cancer care continuum. J Clin Oncol (2013) 2.39
Drugs, cancer and end-of-life care: a case study of pharmaceuticalization? Soc Sci Med (2014) 2.03
A catalyst for change: the European cancer Patient's Bill of Rights. Oncologist (2014) 1.55
Nuclear medicine, scientific publishing and the era of cost containment. Eur J Nucl Med Mol Imaging (2011) 1.50
Review and uses of stereotactic body radiation therapy for oligometastases. Oncologist (2012) 1.25
Effective coverage: a metric for monitoring Universal Health Coverage. PLoS Med (2014) 1.18
Personalizing health care: feasibility and future implications. BMC Med (2013) 1.07
Leveling the playing field: bringing development of biomarkers and molecular diagnostics up to the standards for drug development. Clin Cancer Res (2012) 1.07
Integrating patient reported outcomes with clinical cancer registry data: a feasibility study of the electronic Patient-Reported Outcomes From Cancer Survivors (ePOCS) system. J Med Internet Res (2013) 1.04
Patient experience and attitudes toward addressing the cost of breast cancer care. Oncologist (2014) 1.02
How might healthcare systems influence speed of cancer diagnosis: a narrative review. Soc Sci Med (2014) 1.01
Cost, coverage, and comparative effectiveness research: the critical issues for oncology. J Clin Oncol (2012) 1.01
Appraising iniparib, the PARP inhibitor that never was--what must we learn? Nat Rev Clin Oncol (2013) 1.01
Quantifying the burden of informal caregiving for patients with cancer in Europe. Support Care Cancer (2014) 0.96
Effectiveness of multidimensional cancer survivor rehabilitation and cost-effectiveness of cancer rehabilitation in general: a systematic review. Oncologist (2012) 0.95
Dabigatran - a case history demonstrating the need for comprehensive approaches to optimize the use of new drugs. Front Pharmacol (2013) 0.95
Prices, Costs, and Affordability of New Medicines for Hepatitis C in 30 Countries: An Economic Analysis. PLoS Med (2016) 0.94
Specialist palliative care services for adults with advanced, incurable illness in hospital, hospice, or community settings--protocol for a systematic review. Syst Rev (2015) 0.94
Should positron emission tomography/computed tomography be the first rather than the last test performed in the assessment of cancer? Cancer Imaging (2012) 0.93
Development and economic trends in cancer therapeutic drugs: a 5-year update 2010-2014. Br J Cancer (2015) 0.92
A systematic review and methodological evaluation of published cost-effectiveness analyses of aromatase inhibitors versus tamoxifen in early stage breast cancer. PLoS One (2013) 0.92
Value: The Next Frontier in Cancer Care. Oncologist (2016) 0.92
Drivers of the cost of cancer care. Lancet Oncol (2012) 0.89
Economic studies in colorectal cancer: challenges in measuring and comparing costs. J Natl Cancer Inst Monogr (2013) 0.88
Is there still a role for SPECT-CT in oncology in the PET-CT era? Nat Rev Clin Oncol (2012) 0.86
Rapid learning in practice: a lung cancer survival decision support system in routine patient care data. Radiother Oncol (2014) 0.86
Health economic aspects of breast cancer treatment: the compulsory health insurances' view. Breast Care (Basel) (2013) 0.86
Segmental (18)F-FDG-PET/CT in a single pulmonary nodule: a better cost/effectiveness strategy. Eur J Nucl Med Mol Imaging (2017) 0.86
A review of systematic reviews of the cost-effectiveness of hormone therapy, chemotherapy, and targeted therapy for breast cancer. Breast Cancer Res Treat (2015) 0.85
Does the cancer drugs fund lead to faster uptake of cost-effective drugs? A time-trend analysis comparing England and Wales. Br J Cancer (2014) 0.84
Personalized medicine: does the molecular suit fit? Oncologist (2013) 0.84
Health care costs: how do we decide value? When do we decide? How do we particularize the decisions? Oncologist (2012) 0.84
Out of pocket, out of sight? An unmeasured component of the burden of cancer. J Natl Cancer Inst (2013) 0.84
Modern treatment in chronic lymphocytic leukemia: impact on survival and efficacy in high-risk subgroups. Cancer Med (2014) 0.84
Variation in performance of candidate surgical quality measures for muscle-invasive bladder cancer by hospital type. BJU Int (2014) 0.84
Innovations that reach the patient: early health technology assessment and improving the chances of coverage and implementation. Ecancermedicalscience (2016) 0.84
Cost and effectiveness of image-guided radiotherapy for non-operated localized lung cancer: a population-based propensity score-matched analysis. J Thorac Dis (2015) 0.83
Real world costs and cost-effectiveness of Rituximab for diffuse large B-cell lymphoma patients: a population-based analysis. BMC Cancer (2014) 0.83
Cost of care for cancer patients in England: evidence from population-based patient-level data. Br J Cancer (2016) 0.83
Cost effectiveness after a pancreaticoduodenectomy: bolstering the volume argument. HPB (Oxford) (2014) 0.82
Cost-effectiveness of chemotherapy combined with thoracic radiotherapy versus chemotherapy alone for limited stage small cell lung cancer: A population-based propensity-score matched analysis. Thorac Cancer (2014) 0.82
Economic evaluation of bevacizumab in the treatment of non-small cell lung cancer (NSCLC). Clinicoecon Outcomes Res (2012) 0.82
Translational cancer research: balancing prevention and treatment to combat cancer globally. J Natl Cancer Inst (2014) 0.82
New Highly Active Antiretroviral drugs and generic drugs for the treatment of HIV infection: a budget impact analysis on the Italian National Health Service (Lombardy Region, Northern Italy). BMC Infect Dis (2015) 0.81
Advancing comparative studies of patterns of care and economic outcomes in cancer: challenges and opportunities. J Natl Cancer Inst Monogr (2013) 0.81
Initial treatment for newly diagnosed elderly colorectal cancer patients: patterns of care in Italy and the United States. J Natl Cancer Inst Monogr (2013) 0.81
Validity of breast, lung and colorectal cancer diagnoses in administrative databases: a systematic review protocol. BMJ Open (2016) 0.81
Cost profiles of colorectal cancer patients in Italy based on individual patterns of care. BMC Cancer (2013) 0.81
Challenges related to palliative care. Lancet Oncol (2011) 0.81
Genomic testing to determine drug response: measuring preferences of the public and patients using Discrete Choice Experiment (DCE). BMC Health Serv Res (2013) 0.80
A critical review of recent developments in radiotherapy for non-small cell lung cancer. Radiat Oncol (2016) 0.80
Implementation of cancer clinical care pathways: a successful model of collaboration between payers and providers. J Oncol Pract (2012) 0.79
Cancer-treatment toxicity: can nutrition help? Nat Rev Clin Oncol (2012) 0.79
Health service use and costs in the last 6 months of life in elderly decedents with a history of cancer: a comprehensive analysis from a health payer perspective. Br J Cancer (2016) 0.79
Drugs for solid cancer: the productivity crisis prompts a rethink. Onco Targets Ther (2013) 0.78
Striking a balance between idealism and fatalism. Lancet Oncol (2011) 0.78
GUCY2C molecular staging personalizes colorectal cancer patient management. Biomark Med (2012) 0.78
Recent trends in economic burden of acute myocardial infarction in South Korea. PLoS One (2015) 0.78
Personalized radiotherapy: concepts, biomarkers and trial design. Br J Radiol (2015) 0.77
Analysis of media reporting of The Lancet Oncology Commission. Lancet Oncol (2012) 0.77
Drug waste minimization as an effective strategy of cost-containment in oncology. BMC Health Serv Res (2014) 0.77
Institute of medicine recommendations for improving the quality of cancer care: what do they mean for the general internist? J Gen Intern Med (2014) 0.77
Cost-effectiveness of neoadjuvant concurrent chemoradiotherapy versus esophagectomy for locally advanced esophageal squamous cell carcinoma: A population-based matched case-control study. Thorac Cancer (2015) 0.77
Paediatric oncology: are there ways to bend the costs? Lancet Oncol (2011) 0.77
Learning from the public: citizens describe the need to improve end-of-life care access, provision and recognition across Europe. Eur J Public Health (2013) 0.77
Cost of HAART in Italy: multicentric evaluation and determinants from a large HIV outpatient cohort. Clinicoecon Outcomes Res (2014) 0.77
'Burden to others' as a public concern in advanced cancer: a comparative survey in seven European countries. BMC Cancer (2013) 0.77
Economic impact of genomic diagnostics for intermediate-risk acute myeloid leukaemia. Br J Haematol (2016) 0.77
Affordable cancer care. Lancet Oncol (2012) 0.76
The opportunity cost of cancer care: a statement from NICE. Lancet Oncol (2011) 0.76
What price cure? Lancet Oncol (2012) 0.75
Re: delivering affordable cancer care in high-income countries. J Urol (2012) 0.75
Regulators, payers, and prescribers: can we fill the gaps? Lancet Oncol (2011) 0.75
The cost of cancer care is not related to its outcomes. Ecancermedicalscience (2016) 0.75
Does a too risk-averse approach to the implementation of new radiotherapy technologies delay their clinical use? Br J Radiol (2015) 0.75
The value proposition of molecular medicine. Clin Transl Sci (2012) 0.75
Increasing Receipt of High-Tech/High-Cost Imaging and Its Determinants in the Last Month of Taiwanese Patients With Metastatic Cancer, 2001-2010: A Retrospective Cohort Study. Medicine (Baltimore) (2015) 0.75
Promise and perils of guidelines in quality cancer care. J Oncol Pract (2012) 0.75
Targeted therapies: Manufacturer sponsorship bias in economic analyses matters. Nat Rev Clin Oncol (2012) 0.75
Cost of breast cancer based on real-world data: a cancer registry study in Italy. BMC Health Serv Res (2017) 0.75
Cancer care after the National Health Service reforms. Lancet Oncol (2012) 0.75
Cancer care coordinators in stage III colon cancer: a cost-utility analysis. BMC Health Serv Res (2015) 0.75
Outcomes research: Radiotherapy capacity in Europe--time to even things out? Nat Rev Clin Oncol (2013) 0.75
First do no harm: the review frequency of illness depends as much on family dynamics as on material factors. Br J Gen Pract (2013) 0.75
AIDS and HIV Infection after Thirty Years. AIDS Res Treat (2013) 0.75
First do no harm: evidence sometimes shows the self-evident to be wrong. Br J Gen Pract (2013) 0.75
Healthcare Resource Use and Expenditures among Metastatic Breast Cancer Patients Treated with HER2-Targeted Agents. Int J Breast Cancer (2014) 0.75
Evaluation of the utilization of external radiotherapy in the treatment of localized prostate cancer in Andalusia, Spain. Radiat Oncol (2015) 0.75
Evaluation of the duplication of staging CT scans for localized colon cancer in a Medicare population. Med Care (2014) 0.75
Budget impact analysis of first-line treatment with pazopanib for advanced renal cell carcinoma in Spain. BMC Cancer (2013) 0.75
Utilization of Pharmaceutical Patient and Prescription Assistance Programs via a Pharmacy Department Patient Assistance Program for Indigent Cancer Patients. Hosp Pharm (2016) 0.75
Implementation of a rapid learning platform: Predicting 2-year survival in laryngeal carcinoma patients in a clinical setting. Oncotarget (2016) 0.75
Challenges of radiation oncology in Spain today. Rep Pract Oncol Radiother (2013) 0.75
Close cooperation with Health Technology Assessment expertise is crucial for implementation and ultimately reimbursement of innovations in oncology. Ecancermedicalscience (2016) 0.75
Guidelines: usefulness and limitations. Breast Care (Basel) (2013) 0.75
Cancer care burden: aiming at the Achilles heel. Curr Oncol (2015) 0.75
Catastrophic Health Care Expenditure among Older People with Chronic Diseases in 15 European Countries. PLoS One (2016) 0.75
Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med (2004) 30.26
International network of cancer genome projects. Nature (2010) 20.35
Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer (2002) 15.72
Tumour stem cells and drug resistance. Nat Rev Cancer (2005) 15.21
Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol (2007) 11.77
A genome-wide association scan of tag SNPs identifies a susceptibility variant for colorectal cancer at 8q24.21. Nat Genet (2007) 11.62
Ethical and scientific implications of the globalization of clinical research. N Engl J Med (2009) 11.42
Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet (2004) 11.37
Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet (2002) 10.17
Drug penetration in solid tumours. Nat Rev Cancer (2006) 9.80
ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol (2012) 9.76
Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol (2004) 9.73
Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. Cancer Epidemiol Biomarkers Prev (2005) 9.47
Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol (2007) 9.29
Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol (2003) 8.95
Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J Clin Oncol (2008) 8.72
Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet (2009) 8.69
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol (2008) 7.89
Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. JAMA (2006) 7.81
Increasing carbon storage in intact African tropical forests. Nature (2009) 7.71
Out of bounds? A critique of the new policies on hyperandrogenism in elite female athletes. Am J Bioeth (2012) 7.69
Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis. Cancer Cell (2004) 7.61
Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC Trial. J Natl Cancer Inst (2006) 7.29
Drug resistance and the solid tumor microenvironment. J Natl Cancer Inst (2007) 7.10
Preventing childhood obesity by reducing consumption of carbonated drinks: cluster randomised controlled trial. BMJ (2004) 7.01
Meta-analysis of genome-wide association data identifies four new susceptibility loci for colorectal cancer. Nat Genet (2008) 6.97
Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. Lancet Oncol (2007) 6.82
Abrogation of TGF beta signaling in mammary carcinomas recruits Gr-1+CD11b+ myeloid cells that promote metastasis. Cancer Cell (2008) 6.78
Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol (2007) 6.65
Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J Clin Oncol (2009) 6.44
Efficacy and safety of exercise training in patients with chronic heart failure: HF-ACTION randomized controlled trial. JAMA (2009) 6.36
A genome-wide association study identifies colorectal cancer susceptibility loci on chromosomes 10p14 and 8q23.3. Nat Genet (2008) 6.26
Improved glycemic control in poorly controlled patients with type 1 diabetes using real-time continuous glucose monitoring. Diabetes Care (2006) 6.25
Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol (2005) 6.20
Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. J Clin Oncol (2014) 6.10
A genome-wide association study shows that common alleles of SMAD7 influence colorectal cancer risk. Nat Genet (2007) 6.02
Clinicopathologic correlates of solitary fibrous tumors. Cancer (2002) 5.96
Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation. Clin Cancer Res (2005) 5.44
Actual 10-year survival after resection of colorectal liver metastases defines cure. J Clin Oncol (2007) 4.95
KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur J Cancer (2006) 4.92
Randomized trial of short-course radiotherapy versus long-course chemoradiation comparing rates of local recurrence in patients with T3 rectal cancer: Trans-Tasman Radiation Oncology Group trial 01.04. J Clin Oncol (2012) 4.91
Cutaneous melanoma attributable to sunbed use: systematic review and meta-analysis. BMJ (2012) 4.79
American Society of Clinical Oncology Statement on minimum standards and exemplary attributes of clinical trial sites. J Clin Oncol (2008) 4.79
Merkel cell carcinoma: prognosis and treatment of patients from a single institution. J Clin Oncol (2005) 4.79
In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. Mayo Clin Proc (2015) 4.70
External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study. Lancet Oncol (2010) 4.61
Meta-analysis of risk factors for cutaneous melanoma: II. Sun exposure. Eur J Cancer (2005) 4.55
Adherence to treatment guidelines in clinical practice: study of antipsychotic treatment prior to clozapine initiation. Br J Psychiatry (2012) 4.54
Risks of mortality, myocardial infarction, bleeding, and stroke associated with therapies for age-related macular degeneration. Arch Ophthalmol (2010) 4.50
Histologic subtype and margin of resection predict pattern of recurrence and survival for retroperitoneal liposarcoma. Ann Surg (2003) 4.25
Cancer drugs in the United States: Justum Pretium--the just price. J Clin Oncol (2013) 4.25
Quality of complication reporting in the surgical literature. Ann Surg (2002) 4.21
Web-based survey of fertility issues in young women with breast cancer. J Clin Oncol (2004) 4.03
Critical role of prostate biopsy mortality in the number of years of life gained and lost within a prostate cancer screening programme. BJU Int (2012) 4.01
Proteomic patterns of tumour subsets in non-small-cell lung cancer. Lancet (2003) 4.01
Genetic prognostic and predictive markers in colorectal cancer. Nat Rev Cancer (2009) 3.99
Aberrant epidermal growth factor receptor signaling and enhanced sensitivity to EGFR inhibitors in lung cancer. Cancer Res (2005) 3.98
Solid-pseudopapillary tumor of the pancreas: a surgical enigma? Ann Surg Oncol (2002) 3.96
Common genetic variants at the CRAC1 (HMPS) locus on chromosome 15q13.3 influence colorectal cancer risk. Nat Genet (2007) 3.93
Stereotactic body radiation therapy: the report of AAPM Task Group 101. Med Phys (2010) 3.87
Toward a 21st-century health care system: recommendations for health care reform. Ann Intern Med (2009) 3.85
Pasireotide for postoperative pancreatic fistula. N Engl J Med (2014) 3.84
Pay for performance, quality of care, and outcomes in acute myocardial infarction. JAMA (2007) 3.79
Clinical trials and medical care: defining the therapeutic misconception. PLoS Med (2007) 3.77
The impact of health insurance on health. Annu Rev Public Health (2008) 3.77
Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3. J Clin Oncol (2009) 3.69
Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer. J Clin Oncol (2011) 3.67
Inappropriate prescribing for elderly Americans in a large outpatient population. Arch Intern Med (2004) 3.64
Postoperative nomogram for 12-year sarcoma-specific death. J Clin Oncol (2002) 3.60
Repopulation of cancer cells during therapy: an important cause of treatment failure. Nat Rev Cancer (2005) 3.58
Linking inpatient clinical registry data to Medicare claims data using indirect identifiers. Am Heart J (2009) 3.57
Alcohol poisoning is a main determinant of recent mortality trends in Russia: evidence from a detailed analysis of mortality statistics and autopsies. Int J Epidemiol (2008) 3.56
Postoperative nomogram for disease-specific survival after an R0 resection for gastric carcinoma. J Clin Oncol (2003) 3.56
Adjuvant therapy in the treatment of biliary tract cancer: a systematic review and meta-analysis. J Clin Oncol (2012) 3.56
The TP53 colorectal cancer international collaborative study on the prognostic and predictive significance of p53 mutation: influence of tumor site, type of mutation, and adjuvant treatment. J Clin Oncol (2005) 3.48
Prospective study evaluating the impact of tissue confirmation of metastatic disease in patients with breast cancer. J Clin Oncol (2011) 3.46
A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: a TAX327 study analysis. Clin Cancer Res (2007) 3.41
Global gene expression profiling of circulating tumor cells. Cancer Res (2005) 3.41
NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)--update of the NCCN clinical practice guidelines. J Natl Compr Canc Netw (2007) 3.40
Phase I pharmacokinetic and biologic correlative study of mapatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factor-related apoptosis-inducing ligand receptor-1. J Clin Oncol (2007) 3.37
Factors associated with failure to publish large randomized trials presented at an oncology meeting. JAMA (2003) 3.36
Heart failure and a controlled trial investigating outcomes of exercise training (HF-ACTION): design and rationale. Am Heart J (2007) 3.34
Prevalence, incidence and nature of prescribing errors in hospital inpatients: a systematic review. Drug Saf (2009) 3.34
A selective approach to the resection of cystic lesions of the pancreas: results from 539 consecutive patients. Ann Surg (2006) 3.34
Activity of sunitinib in patients with advanced neuroendocrine tumors. J Clin Oncol (2008) 3.34
Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM-7). Eur Urol (2003) 3.31
Perceptions of patients and physicians regarding phase I cancer clinical trials: implications for physician-patient communication. J Clin Oncol (2003) 3.31
Gene expression signature to improve prognosis prediction of stage II and III colorectal cancer. J Clin Oncol (2010) 3.30
Breast cancer. Lancet (2005) 3.27
Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysis. Lancet Oncol (2009) 3.26
Mass spectrometry to classify non-small-cell lung cancer patients for clinical outcome after treatment with epidermal growth factor receptor tyrosine kinase inhibitors: a multicohort cross-institutional study. J Natl Cancer Inst (2007) 3.25
Subtype specific prognostic nomogram for patients with primary liposarcoma of the retroperitoneum, extremity, or trunk. Ann Surg (2006) 3.23
Lay-led self-management in chronic illness: a review of the evidence. Chronic Illn (2006) 3.22
The role of ABC transporters in clinical practice. Oncologist (2003) 3.21
'Environment' in cancer causation and etiological fraction: limitations and ambiguities. Carcinogenesis (2007) 3.20
Italian randomized trial among women with hysterectomy: tamoxifen and hormone-dependent breast cancer in high-risk women. J Natl Cancer Inst (2003) 3.20